The role of routine hearing screening in children with cystic fibrosis on aminoglycosides: A systematic review

Farzal, Zainab; Kou, Yann Fuu; John, Rachel St.; Shah, Gopi; Mitchell, Ron B.

doi:10.1002/lary.25409

Cited by 15 publications

(20 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Discussionmentioning

confidence: 99%

“…Ototoxicity with sensorineural hearing loss due to aminoglycosides occurs at the level of cochlear hair cells secondary to the generation of reactive oxygen specimens [30]. Because hair cells at the basal turn of the cochlea are affected first, high-frequency hearing loss is one of the first findings, occurring as early as 4 hours after treatment [30]. Aminoglycoside toxicity might involve a genetic predisposition, at least as a contributing factor: several mitochondrial gene mutations in the MT-RNR1 and MT-TS1 groups (including the mitochondrial 1555a>G mutation) might be culpable [30–32], and many studies have compared the efficacy and toxic potential of different regimens of antibiotics in CF patients, with varying results [15, 20, 32–34].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Changes in the inner ear structures in cystic fibrosis patients

Pauna

Monsanto

Kurata

et al. 2017

International Journal of Pediatric Otorhinolaryngology

View full text Add to dashboard Cite

Objective Although prolonged use of antibiotics is very common in cystic fibrosis (CF) patients, no studies have assessed the changes in both cochlear and peripheral vestibular systems in this population. Methods We used human temporal bones to analyze the density of vestibular dark, transitional, and hair cells in specimens from CF patients who were exposed to several types of antibiotics, as compared with specimens from an age-matched control group with no history of ear disease or antibiotic use. Additionally, we analyzed the changes in the elements of the cochlea (hair cells, spiral ganglion neurons, and the area of the stria vascularis). Data was gathered using differential interference contrast microscopy and light microscopy. Results In the CF group, 83% of patients were exposed to some ototoxic drugs, such as aminoglycosides. As compared with the control group, the density of both type I and type II vestibular hair cells was significantly lower in all structures analyzed; the number of dark cells was significantly lower in the lateral and posterior semicircular canals. We noted a trend toward a lower number of both inner and outer cochlear hair cells at all turns of the cochlea. The number of spiral ganglion neurons in Rosenthal’s canal at the apical turn of the cochlea was significantly lower; furthermore, the area of the stria vascularis at the apical turn of the cochlea was significantly smaller. Conclusions Deterioration of cochlear and vestibular structures in CF patients might be related to their exposure to ototoxic antibiotics. Well-designed case-control studies are necessary to rule out the effect of CF itself.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Changes in the inner ear structures in cystic fibrosis patients

Pauna

Monsanto

Kurata

et al. 2017

International Journal of Pediatric Otorhinolaryngology

View full text Add to dashboard Cite

show abstract

“…Their use is also increasing due to emerging multidrug-resistant pathogens, e.g., in the treatment of cystic fibrosis and tuberculosis (3,7). The long-term daily administration of aminoglycosides required to manage these conditions results in a high incidence of hearing loss, affecting the quality of life (8,9).…”

Section: Introductionmentioning

confidence: 99%

Identification of ion-channel modulators that protect against aminoglycoside-induced hair cell death

Kenyon¹,

Kirkwood²,

Kitcher³

et al. 2017

JCI Insight

View full text Add to dashboard Cite

“…Studies demonstrate that AG ototoxicity is directly correlated with the number of treatment courses, hence the cumulative dose [10] , [13] , [17] . One recent systematic review including twelve studies conducted between 1979 and 2014 reported an overall SNHL prevalence of 0–29% in CF children treated with aminoglycosides; this was increased to 44% if the number of treatment courses was more than 10 [18] . Also in our study 2 of the 4 patients in the CF group with SNHL had been exposed to more than 8 courses of amikacin.…”

Section: Discussionmentioning

confidence: 99%

Does amikacin treatment cause subclinical hearing loss in patients with cystic fibrosis?

et al. 2016

View full text Add to dashboard Cite

IntroductionAminoglycosides (AGs) have been widely used for potential life-threatening bacterial infections. Although AGs are well known for their ototoxic side effects, some AGs such as amikacin are considered less harmful to auditory functions; thus, auditory monitoring is mostly neglected during treatment with these drugs.ObjectiveTo reflect the potential auditory hazards of repeated amikacin use on the patients with cystic fibrosis (CF).Method32CF patients with prior exposure to at least 3 courses of amikacin (the CF group) and 35 non-CF patients visiting the outpatient clinic with any complaint other than hearing loss and no history of treatment with any AG(the control, or C group) were compared with pure-tone audiometry(PTA). The diagnosis of CF was made by Nanoduck sweat test.ResultsThe average age of the participants were 8.25 ± 2.76 years in the CF group and 8.58 ± 2.00 years in the C group (ranging from 5 to 13 years). 29 (43.28%) of the cases were female and 38 (56.71%) were male. Clinical SNHL(sensorineural hearing loss) was detected in 4 of the 32 subjects in the CF group. None of the subjects in the C group exhibited clinical SNHL. There was no statistically significant difference between the groups with regard to presence or absence of clinical SNHL (p > 0.05). However, hearing levels of the CF group were around 20 dB(decibel) HL(hearing loss), whereas hearing levels of the C group were around 5 dB. This difference was statistically significant for the pure tone averages of both all frequencies and speech frequencies (p < 0.05).ConclusionRepetitive exposure to AGs can cause permanent, although mild, sensorineural hearing loss. For prevention, hearing status of the patient should be closely monitored and treatment of choice should be precisely tailored according to the audiological evaluation. This is especially important in patients with CF who frequently experience medical conditions necessitating AGs use.

show abstract

The role of routine hearing screening in children with cystic fibrosis on aminoglycosides: A systematic review

Cited by 15 publications

References 36 publications

Changes in the inner ear structures in cystic fibrosis patients

Changes in the inner ear structures in cystic fibrosis patients

Identification of ion-channel modulators that protect against aminoglycoside-induced hair cell death

Does amikacin treatment cause subclinical hearing loss in patients with cystic fibrosis?

Contact Info

Product

Resources

About